Disclosure: A. Miki, Santen Pharmaceuticals (F, R), Sensimed (F), Nitto Medic (R), Pfizer Japan (R), Otsuka Pharmaceuticals (R), Novartis Pharma (R), Topcon (R), SEED (R), Senju Pharmaceutical (R), Kowa Pharmaceuticals (R); Y. Yasukura, None; R.N. Weinreb, Carl Zeiss Meditec (F, R), Genentech (F), Heidelberg Engineering (F), Konan (F), National Eye Institute (F), Neurovision (F), Optoview (F), Quark (F), Reichart (F), Tomey (F), Topcon (F), Alcon (C), Allergan (C), Ametek (C), Bausch&Lomb (C), Carl Zeiss Meditec (C), Topcon (C), Valent Pharmaceuticals (C), N. Maeda, JSPS Kakenhi (F), Alcon Laboratories, Inc (C), Santen Pharmaceuticals (R); Otsuka Pharmaceuticals (R), Topcon (R), Abbott Medical Optics (R), Johnson & Johnson (R), Tomey (R) T. Yamada, None; S. Koh, Johnson & Johnson (F, R), Santen Pharmaceuticals (SK), Otsuka Pharmaceuticals (R), Novartis Pharma (R), Menicon (R), Oculus (R), SEED (F, R) ; T. Asai, None; Y. Ikuno, Tomey (F), Topcon (F), Bayer Yakuhin (C), Novartis Pharma (C); K. Nishida, Topcon (F), Menicon (F), Wakamoto (F), Rohto Pharmaceutical (F), MSD Japan (F), Senju Pharmaceutical (F), Pfizer Japan (F), Santen Pharmaceutical (F, R), Otsuka Pharmaceutical (F, R), Novartis Pharma (F), HOYA (F), Kowa Pharmaceuticals (F), AMO Japan (F), Pfizer Japan (R), Novartis Pharma (R), Johnson & Johnson (R), Senju Pharmaceutical (R), HOYA (R), Kowa Pharmaceuticals (R), Boehringer Ingelheim Japan (R), Bayer Yakuhin (R), SEED (R), Nikon Health Care (R)